ASBP
Aspire BioPharma, Inc.
NASDAQ: ASBP · HEALTHCARE · BIOTECHNOLOGY
$0.22
-9.30% today
Updated 2026-04-30
Market cap
$1.03M
P/E ratio
—
P/S ratio
166.07x
EPS (TTM)
$-16.38
Dividend yield
—
52W range
$0 – $35
Volume
12.1M
Aspire BioPharma, Inc. (ASBP) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $6202.00 |
| Revenue growth (YoY) | — | — | — | — | — |
| Cost of revenue | — | $0.00 | $0.00 | $0.00 | $6318.00 |
| Gross profit | — | $0.00 | $0.00 | $0.00 | $-116.00 |
| Gross margin | — | — | — | — | -1.9% |
| R&D | — | $175316.00 | $72050.00 | $144356.00 | $923914.00 |
| SG&A | $27791.00 | $976345.00 | $1.34M | $3.09M | $17.64M |
| Operating income | $-25480.00 | $-976345.00 | $-1.34M | $-3.09M | $-19.35M |
| Operating margin | — | — | — | — | -312016.9% |
| EBITDA | $-25480.00 | $3.34M | $5.80M | $-11.65M | $-19.35M |
| EBITDA margin | — | — | — | — | -312016.9% |
| EBIT | $-53271.00 | $-596491.00 | $4.46M | $-1.21M | — |
| Interest expense | — | $0.00 | $8966.00 | $892000.00 | $8.53M |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-25475.00 | $3.34M | $4.46M | $-12.54M | $-24.48M |
| Net income growth (YoY) | — | +13210.9% | +33.7% | -380.8% | -95.3% |
| Profit margin | — | — | — | — | -394725.1% |